NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders’ Meeting will be held on January 31, 2023. Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely. About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. For more information, please visit www.Enzo.com or follow Enzo Biochem on Twitter and LinkedIn. Forward-Looking Statements Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2022. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. ### Enzo Biochem Contacts For: Enzo Biochem:For Media:For Investors:David Bench, CFO 212-583-0100 dbench@enzo.comLynn Granito Berry & Company PR 212-253-8881 lgranito@berrypr.comChris Calabrese LifeSci Advisors, LLC 917-680-5608 ccalabrese@lifesciadvisors.com